Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bisantrene Combinations for AML with Extramedullary Disease
NCT05456269Phase 1Withdrawn
- Sponsor
- Race Oncology
- Start
- Jul 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bisantrene in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (2 arms), sponsored by Race Oncology. Primary endpoints: Dose confirmation at 8 weeks, Overall Response at 4 weeks and 1 more. Planned start Jul 2022; status: withdrawn.
02
Drugs
bisantrene
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05456269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05456269.